Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.
Use of the novel quality improvement tool ‘Eat, Sleep, and Console’ (ESC) markedly reduced the length of hospitalization stay (LOS) and post-natal use of opiate medications in infants with in utero opioid exposure, according to data presented at PAS 2019.
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
The risk of miscarriage is lowest at age 27 years but increases with older age and by up to four times after three consecutive previous miscarriages, according to a Norway study. This risk is also associated with earlier pregnancy complications, including stillbirth, preterm delivery and gestational diabetes.